Immune Pharmaceuticals seems to be undervalued based on Macroaxis valuation methodology. This module calculates value of Immune Pharmaceuticals from evaluating the corporation fundamentals such as Shares Owned by Institutions of
0.06%, Current Valuation of 8.67M and Return On Asset of (42.63)% as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage to acquire undervalued assets and to sell overvalued assets since at some point stocks prices and their ongoing real values will come together.
|Horizon||30 Days Login to change|
Immune Pharmaceuticals is currently regarded as number one stock in price to sales category among related companies. It is currently regarded as number one stock in price to earning category among related companies .
|Price to Sales ( times )|
|Price to Earning ( times )|